App-Quantinova.ai

The feasibility of detailed phenotyping of muscle mitochondrial respiratory chain function and content in Parkinson’s disease

A. Yarnall - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Parkinson's disease

N/A

The genetic study of hereditary chorea in Kazakhstan

R. Kaiyrzhanov - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Movement disorders

N/A

The incidence, predictors, and outcomes of delirium in Parkinson’s disease and atypical parkinsonism

S. Green - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The non-declaration of musculoskeletal pain in Parkinson’s disease in patient-related outcome measures –The King’s experience

K. Rukavina - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

The UP study – Ursodeoxycholic acid (UDCA) as neuroprotective treatment for Parkinson’s disease

T. Payne - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Ursodeoxycholic acid

Time matters in brain health: how can health systems respond to the growing demand for genetic testing?

A. Noyce - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Trajectories of pain in newly diagnosed Parkinson’s disease

J. Naisby - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Type 2 diabetes mellitus may worsen severity of motor symptoms in people with Parkinson’s disease

A. Ben-Joseph - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 2 diabetes mellitus

N/A

Unmet psychological needs of People with Parkinson’s disease

M. Turner - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Using a Delphi process to inform the design of disease modifying trials in Parkinson’s disease

M. Zeissler - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Using telemedicine and wearable technology to establish a virtual clinic for people with Parkinson’s

L. Evans - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

BIOMARKER EVALUATION FOR IMIPRIDONE ONC206 REVEALS ClpP, ATF4, MYC, EGFR and HIF1 AS KEY PREDICTORS OF ANTI-CANCER EFFICACY

Sara Morrow - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Dopamine hydrochloride

ASSESSING THE IMPACT OF CORONAVIRUS 19 PANDEMIC ON NEURO-ONCOLOGY AT GUY’S CANCER CENTRE LONDON

Jessica Little - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

BRAIN TUMOURS AND COVID-19: THE PATIENT AND CAREGIVER EXPERIENCE

Mathew Voisin - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Cerebral metastases

N/A

THE BRAIN TUMOR AND NOT FOR PROFIT AND CHARITY EXPERIENCE OF COVID 19: REACTING AND ADJUSTING TO AN UNPRECEDENTED GLOBAL PANDEMIC IN THE 21ST CENTURY

Mary Ellen Maher - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Brain cancer

N/A

COVIDNEUROONC: A UK MULTI-CENTRE, PROSPECTIVE COHORT STUDY OF THE IMPACT OF THE COVID-19 PANDEMIC ON THE NEURO-ONCOLOGY SERVICE

Daniel Fountain - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

TELEPHONE CONSULTATIONS IN NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: LEVELS OF PATIENT SATISFACTION AND COMPARISON WITH TRADITIONAL FACE-TO-FACE CONSULTATIONS

Emma Toman - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT

Maciej Mrugala - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

PELAREOREP AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) WITH STANDARD CHEMORADIOTHERAPY/ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS: REOGLIO PHASE I TRIAL RESULTS

Jessica Kendall - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

ONCOLYTIC VIRUS FOR DIPG: THE CLINICAL EXPERIENCE WITH DNX-2401

Marta M Alonso - Society for Neuro-Oncology (SNO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Diffuse intrinsic pontine glioma

Delta-24-RGD-4C

Filters

45280 Abstracts